REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,062.75 |
| 52 Week High | US$1,062.75 |
| 52 Week Low | US$1,009.10 |
| Beta | 0.12 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| REGN | PE Biotechs | PE Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how REGN performed against the PE Biotechs industry.
Return vs Market: Insufficient data to determine how REGN performed against the PE Market.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 2.8% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in PE Market | 0% |
| 10% least volatile stocks in PE Market | 0% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine REGN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 13,926 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market cap | US$112.54b |
| Earnings (TTM) | US$4.32b |
| Revenue (TTM) | US$13.49b |
26.0x
P/E Ratio8.3x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$13.49b |
| Cost of Revenue | US$6.30b |
| Gross Profit | US$7.19b |
| Other Expenses | US$2.86b |
| Earnings | US$4.32b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | 40.04 |
| Gross Margin | 53.27% |
| Net Profit Margin | 32.04% |
| Debt/Equity Ratio | 7.0% |
How did REGN perform over the long term?
See historical performance and comparison